SecBot SecBot
6-K ·Filed Jul 9, 2026

RDY

DR REDDYS LABORATORIES LTD
BEARISH
Impact 5/10
Horizonweeks Processed4mo ago SEC0001575872-26-000489
Notable filing: 6-K
Actionable Insight ▼ Bearish

Monitor the conference call for root cause and timeline. The delay could allow competitors to capture market share in the generic semaglutide space. Assess if Dr. Reddy's revises guidance in upcoming quarters.

DirectionBearish
Confidencehigh
Horizonweeks

Drug in focus

RDY drug pipeline →

semaglutide

◆ Mixed Named in this 6-K
Impact
Phase
Approved - Generic
Time to market
Already launched in India (March 2026) and Canada (May 2026), but supply halted until ~October 2026 due to API impurity. US market entry not expected until patent exclusivity ends ~2031-2032.
Next catalyst
None dated

What to watchWatch for Dr. Reddy's API remediation progress and the late-October 2026 supply restart timeline. The supply halt halved the FY27 production target from 12M to 6-7M pens and erased ~$678M in market cap. Any update on resolving the impurity issue, regulatory findings, or competitive dynamics (Apotex, USV) could move shares. US market entry (2031-2032 patent expiry) is the long-term prize but too distant to trade on now.

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$13.89
T+0 close · Jul 9, 2026 · via day close
Latest settled
−11.81%
T+60 · $12.25
Vs SPY
−13.44%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 9 $13.89entry
  2. T+1 · 4mo ago −5.04%α −5.47% · $13.19
  3. T+5 · 4mo ago −8.57%α −8.44% · $12.70
  4. T+20 · 3mo ago −12.81%α −15.06% · $12.11
  5. T+60 · 7w ago −11.81%α −13.44% · $12.25
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dr. Reddy's disclosed that certain batches of semaglutide (a key metabolic therapy) were found out of specification due to an API issue, delaying commercial supplies until the root cause is resolved. No patient safety impact or effect on existing regulatory filings, but the delay creates near-term revenue uncertainty for a high-demand product.

Key Facts

  • Semaglutide batches out of specification due to API issue
  • Commercial supplies delayed until root cause resolved
  • No impact on patient safety or existing global regulatory filings
  • Management conference call scheduled for July 9, 2026 at 16:30 IST

Financial Impact

Commercial delay of semaglutide; undisclosed revenue exposure as no financial figures provided in filing

revenueproduct supply

Risk Factors

  • Extended delay could impair competitive positioning
  • Potential regulatory scrutiny or remediation costs
  • Revenue shortfall if semaglutide was a near-term growth driver

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
52% bullish (44 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001575872-26-000489
Document: 0001575872-26-000489-index.html0001575872-26-000489
Document: 0001575872-26-000489.txt0001575872-26-000489

Track record

73 reports on RDY

Performance horizon

6 of 11 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 6 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
  2. Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
  3. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
  4. Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
  5. Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
  6. Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
  7. Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  8. Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  9. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
  10. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
Showing 10 of 73

US Market Status

Market Closed · Opens in 5h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 9, 2026